Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Bone marrow derived mesenchymal stem/stromal cells transduced with full length human TRAIL repress the growth of rhabdomyosarcoma cells in vitro.

Literature DB >> 21357712

Bone marrow derived mesenchymal stem/stromal cells transduced with full length human TRAIL repress the growth of rhabdomyosarcoma cells in vitro.

Helga Barti-Juhasz, Rudolf Mihalik, Katalin Nagy, Giulia Grisendi, Massimo Dominici, Istvan Petak.

Abstract

Entities: Disease Gene Species

Mesh：

Substances：

Year: 2011 PMID： 21357712 PMCID： PMC3046290 DOI： 10.3324/haematol.2010.036822

Source DB: PubMed Journal: Haematologica ISSN： 0390-6078 Impact factor: 9.941

× No keyword cloud information.

12 in total

Review 1. Mesenchymal stem cells: a new promise in anticancer therapy.

Authors: Sabino Ciavarella; Massimo Dominici; Franco Dammacco; Franco Silvestris
Journal: Stem Cells Dev Date: 2010-09-14 Impact factor: 3.272

2. Adipose-derived mesenchymal stem cells as stable source of tumor necrosis factor-related apoptosis-inducing ligand delivery for cancer therapy.

Authors: Giulia Grisendi; Rita Bussolari; Luigi Cafarelli; Istvan Petak; Valeria Rasini; Elena Veronesi; Giorgio De Santis; Carlotta Spano; Mara Tagliazzucchi; Helga Barti-Juhasz; Laura Scarabelli; Franco Bambi; Antonio Frassoldati; Giulio Rossi; Christian Casali; Uliano Morandi; Edwin M Horwitz; Paolo Paolucci; Pierfranco Conte; Massimo Dominici
Journal: Cancer Res Date: 2010-04-13 Impact factor: 12.701

3. Pediatric rhabdomyosarcoma cell lines are resistant to Fas-induced apoptosis and highly sensitive to TRAIL-induced apoptosis.

Authors: I Petak; L Douglas; D M Tillman; R Vernes; J A Houghton
Journal: Clin Cancer Res Date: 2000-10 Impact factor: 12.531

4. Gene therapy using TRAIL-secreting human umbilical cord blood-derived mesenchymal stem cells against intracranial glioma.

Authors: Seong Muk Kim; Jung Yeon Lim; Sang In Park; Chang Hyun Jeong; Ji Hyeon Oh; Moonsup Jeong; Wonil Oh; Sang-Hoon Park; Young-Chul Sung; Sin-Soo Jeun
Journal: Cancer Res Date: 2008-12-01 Impact factor: 12.701

5. Influence of casein kinase II in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human rhabdomyosarcoma cells.

Authors: Kamel Izeradjene; Leslie Douglas; Addison Delaney; Janet A Houghton
Journal: Clin Cancer Res Date: 2004-10-01 Impact factor: 12.531

6. Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy.

Authors: Laura S Sasportas; Randa Kasmieh; Hiroaki Wakimoto; Shawn Hingtgen; Jeroen A J M van de Water; Gayatry Mohapatra; Jose Luiz Figueiredo; Robert L Martuza; Ralph Weissleder; Khalid Shah
Journal: Proc Natl Acad Sci U S A Date: 2009-03-05 Impact factor: 11.205

7. A caspase-8-independent component in TRAIL/Apo-2L-induced cell death in human rhabdomyosarcoma cells.

Authors: I Petak; R Vernes; K S Szucs; M Anozie; K Izeradjene; L Douglas; D M Tillman; D C Phillips; J A Houghton
Journal: Cell Death Differ Date: 2003-06 Impact factor: 15.828

8. Mesenchymal stem cell delivery of TRAIL can eliminate metastatic cancer.

Authors: Michael R Loebinger; Ayad Eddaoudi; Derek Davies; Sam M Janes
Journal: Cancer Res Date: 2009-05-12 Impact factor: 12.701

Review 9. TRAIL receptor signalling and modulation: Are we on the right TRAIL?

Authors: Devalingam Mahalingam; Eva Szegezdi; Maccon Keane; Steven de Jong; Afshin Samali
Journal: Cancer Treat Rev Date: 2008-12-30 Impact factor: 12.111

10. Application of multipotent mesenchymal stromal cells in pediatric patients following allogeneic stem cell transplantation.

Authors: Ingo Müller; Sandra Kordowich; Christina Holzwarth; Gesa Isensee; Peter Lang; Felix Neunhoeffer; Massimo Dominici; Johann Greil; Rupert Handgretinger
Journal: Blood Cells Mol Dis Date: 2007-09-14 Impact factor: 3.039

3 in total